Therapeutic proteins such as monoclonal antibodies (mAbs) can be subject to physical or chemical stress during the manufacturing process and supply chain. A common chemical degradation is the deamidation of the amino acid asparagine to aspartic acid or iso-aspartic acid. Modification of glutamine to glutamic acid is also possible, although this occurs at a slower rate. When deamidation occurs in the antigen binding region of the mAb, it can result in a loss of potency.
Bio-Techne brands Novus Biologicals® and R&D Systems® were proud to support the 2nd International Antibody Validation Meeting held at Bath University, on the 15-16 September, 2016. Almost 100 participants from around the world, including funders, publishers, academics, pharma and antibody manufacturers were in attendance, to share and discuss best practices in research antibody validation and to drive improved antibody validation standards for the global life science community.
